دانلود مقاله با موضوع تولواپتان در بیماران ADPKD با بسیار عملکرد پایین کلیه
در قالب pdf و در 8 اسلاید،قابل ویرایش، شامل:
موضوع انگلیسی:Tolvaptan in ADPKD Patients With Very
Low Kidney Function
بخشی از متن:Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with autosomal
dominant polycystic kidney disease (ADPKD) in TEMPO 3:4 and REPRISE trials. Tolvaptan effects in
subjects with eGFR 15 to 24 ml/min per 1.73 m2 were not investigated. This post hoc analysis retrospectively
investigated eGFR decline in REPRISE versus an open-label, phase 3b extension trial (open-label
extension [OLE] NCT02251275) in subjects who received placebo in REPRISE and tolvaptan in OLE with
eGFR 15 to 24 and 25 to 29 ml/min per 1.73 m2, respectively.
Methods: One data subset comprised subjects with OLE baseline eGFR 15 to 29 ml/min per 1.73 m2 who
had received placebo in REPRISE and began tolvaptan in OLE. The second comprised subjects who had
received tolvaptan in REPRISE and were matched to REPRISE placebo-treated subjects for REPRISE
baseline characteristics. Annualized eGFR slopes in REPRISE versus OLE were compared within the
REPRISE placebo (i.e., placebo vs. tolvaptan treatment) and tolvaptan (i.e., 2 periods of tolvaptan treatment)
subsets.
